Recursion Q1 net loss narrows to $117.5M; REC-1245 safety data positive, REC-4539 dosed

RECURSION PHARMACEUTICALS, INC.

2026-Q1 EPS reported -$0.22 revenue$6,472,000

Net loss of $117.5M vs $202.5M YoY; revenue $6.5M, down 56% YoY on lower Roche milestone phasing.
Cash & equivalents $665.2M; 2026 cash burn guidance <$390M, runway into early 2028 without financing.
REC-1245 (RBM39 degrader): No DLTs in 16 patients; well-tolerated with dose-dependent PK; dose escalation ongoing.
REC-4881 (MEK1/2) in FAP: 43% median polyp burden reduction at Week 13; FDA engagement for registrational path begun.
REC-4539 (LSD1 inhibitor): First patient dosed in Phase 1 ENLYGHT study; reversible design to reduce platelet toxicity.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RECURSION PHARMACEUTICALS, INC. updated its first quarter ended March 31, 2026 guidance (reaffirmed).

Period: first quarter ended March 31, 2026
Guidance: reaffirmed
Result: reported results

Exact text from the filing

today reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement, as well as financial results for its first quarter ended March 31, 2026.

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-26-000077

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.